FDA Panel Rejects Roxadustat for Anemia in Kidney Disease FDA Panel Rejects Roxadustat for Anemia in Kidney Disease

An FDA advisory committee voted by 1-13 and 2-12 margins against approving a novel, oral agent, roxadustat, for treating anemia in patients with chronic kidney disease. Safety was the major issue.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Nephrology News Source Type: news